The husband-and-wife duo who founded BioNTech, Uğur Şahin and Özlem Türeci, have announced their departure from top executive roles to launch a new mRNA-focused entity, coinciding with a period of deepening financial losses for the German biotech firm.
Leadership transition and independent innovation BioNTech’s full-year 2025 financial report confirmed that CEO Uğur Şahin and Chief Medical Officer Özlem Türeci will step down by the end of 2026. Their new venture will specialize in advancing mRNA technologies with separate funding and operations. However, BioNTech plans to contribute specific technical assets to the startup to accelerate the development of next-generation candidates.
Financial performance and market volatility The shakeup comes as the group reported a 25% drop in Q4 2025 revenue compared to the previous year. Net losses for 2025 surged by 57%, reaching 1.1 billion Euro. This financial downturn stems from the waning global demand for pandemic-related therapeutics, which has seen BioNTech’s share price tumble more than 75% from its 2021 record highs.
Strategic pivot to oncology To stabilize its bottom line, BioNTech is refocusing its efforts on becoming a fully integrated oncology powerhouse. The company currently has over 25 Phase II and III programs underway. Key strategic moves include an 11 billion USD partnership with Bristol Myers Squibb to develop a potential blockbuster cancer drug and the 1.25 billion USD acquisition of rival CureVac to expand its immunotherapy pipeline.
This leadership exit occurs amidst a challenging regulatory environment for the mRNA sector in the U.S., characterized by federal funding cuts and increased scrutiny, adding a layer of uncertainty to the future of mRNA-based medicine.